SAN DIEGO—(BUSINESS WIRE)—Sept. 12, 2006—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at the following investor conferences:
- The Bank of America 36th Annual Investment Conference onTuesday, September 19, 2006, at 10:00 a.m. Pacific Time at TheRitz-Carlton Hotel in San Francisco.
- The 2006 UBS Global Life Sciences Conference on Tuesday,September 26, 2006, at 12:30 p.m. Eastern Time at the GrandHyatt New York Hotel in New York City.
Live webcasts of these presentations will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website throughOctober 10, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive Phase II-stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at large unmet medicalneeds, including schizophrenia, Parkinson's disease, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief
Financial Officer
(858) 558-2871